Japan « Science and Enterprise

Trial Shows Drug Not Extending Breast Cancer Survival Time

By Alan, on July 25th, 2014%

(National Cancer Institute)

25 July 2014. A late-stage clinical trial of the cancer drug sorafenib shows the drug, combined with the chemotherapy drug capecitabine, does not extend the amount of progression-free survival time of advanced breast cancer patients, compared to capecitabine alone. Sorafenib, marketed under the brand name Nexavar, is made by Onyx . . . → Read More: Trial Shows Drug Not Extending Breast Cancer Survival Time

Electronic Circuits Developed That Become Flexible in Body

By Alan, on May 13th, 2014%

Jonathan Reeder (Univ of Texas – Dallas)

13 May 2014. Engineers and material scientists from University of Texas in Dallas and University of Tokyo in Japan developed electronic circuits encased in polymers that become flexible and adapt their shape to three-dimensional objects when implanted in mammals. The team from the labs of Walter . . . → Read More: Electronic Circuits Developed That Become Flexible in Body

Daiichi Sankyo, UCSF Partner on Neurodegenerative Disorders

By Alan, on April 4th, 2014%

3-D brain wiring illustration (NIH)

4 April 2014. The pharmaceutical company Daiichi Sankyo in Tokyo and University of California in San Francisco (UCSF) are collaborating on discovering new drugs to treat neurodegenerative conditions such as Alzheimer’s, Parkinson’s, and Creutzfeldt-Jakob disease. While funding amounts were not disclosed, the deal gives Daiichi Sankyo the option . . . → Read More: Daiichi Sankyo, UCSF Partner on Neurodegenerative Disorders

Pharma Alliance Extends Cancer Antibodies to Eye Disorders

By Alan, on March 4th, 2014%

(Paleontour/Flickr)

4 March 2014. Santen Pharmaceutical Co. in Osaka, Japan is licensing antibodies developed as a cancer therapy by Tracon Pharmaceuticals in San Diego as treatments for eye diseases. Tracon is expected to earn $10 million in an upfront payment from Santen, as well as undisclosed milestone payments and royalties.

Tracon develops biologic . . . → Read More: Pharma Alliance Extends Cancer Antibodies to Eye Disorders

Large Genomic Study Finds New Rheumatoid Arthritis Targets

By Alan, on December 26th, 2013%

(National Institutes of Health)

An international consortium of 70 institutions and companies combined genome-wide analyses with current drug databases to uncover new genomic targets for rheumatoid arthritis, and identify drugs for other diseases with the potential to treat the disorder. The team led by Robert Plenge of Harvard Medical School and the Broad . . . → Read More: Large Genomic Study Finds New Rheumatoid Arthritis Targets

Radiation Sensors Launched in Open-Source Satellites

By Alan, on August 6th, 2013%

ArduSat illustration (NanoSatisfi)

Radiation sensors made by Libelium, a developer of wireless sensor hardware in Zaragoza, Spain are part of the payload contained in CubeSat satellites launched this past weekend on a cargo mission by the Japan Aerospace Exploration Agency. The sensors are part of the first two ArduSat satellites made by open-platform . . . → Read More: Radiation Sensors Launched in Open-Source Satellites

Ball-Mounted Cam Provides Unique View of Football Field

By Alan, on February 27th, 2013%

Football-mounted video camera (Robotics Institute, Carengie Mellon University)

Engineers at Carnegie Mellon University in Pittsburgh and University of Electro-Communications (UEC) in Tokyo designed a miniature video camera mounted inside a football, with an algorithm to process the images, to provide a view of the game rarely, if ever, seen. Carnegie Mellon’s Kris Katani . . . → Read More: Ball-Mounted Cam Provides Unique View of Football Field

Takeda Pharma to Acquire Envoy Therapeutics

By Alan, on November 7th, 2012%

(James. J. Caras, National Science Foundation)

Takeda Pharmaceuticals, in Osaka, Japan, will acquire the drug discovery company Envoy Therapeutics in Jupiter, Florida for $140 million. Takeda says the merger will mean moving Envoy’s management and scientific staff to Takeda’s San Diego offices after March 2013.

Envoy was founded by biophysicist and 2000 Nobel . . . → Read More: Takeda Pharma to Acquire Envoy Therapeutics

Merck, Seiko Epson to Partner on Organic LED Inkjet Inks

By Alan, on October 24th, 2012%

The chemical company Merck in Darmstadt, Germany will license ink-jet ink technology from electronics manufacturer Seiko Epson in Tokyo for the manufacture of organic light-emitting diode (OLED) television displays. Financial terms of the agreement were not disclosed.

OLEDs use thin films of carbon-based materials — thus the name “organic” — placed between two conductors. When . . . → Read More: Merck, Seiko Epson to Partner on Organic LED Inkjet Inks

FDA Approves Drug to Treat Seizures in Epilepsy Patients

By Alan, on October 22nd, 2012%

(National Institute of Drug Abuse)

The U.S. Food and Drug Administration approved the drug perampanel, given in tablet form to treat partial onset seizures in patients with epilepsy ages 12 years and older. Perampanel is marketed under the brand name Fycompa by Eisai Inc. of Woodcliff Lake, New Jersey, and headquartered in Tokyo.

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise